Most Recent
A shareholder class action alleges Cochlear knew months before announcing a profit downgrade that weakening US demand, financial pressures on hospitals and problems with its new Nexa implant made its FY26 earnings guidance unreliable.
Hearing implant giant Cochlear faces a second shareholder class action following two forecast downgrades that wiped billions of dollars from the company's market value.
Hearing implant manufacturer Cochlear has been hit with a shareholder class action alleging its FY26 profit forecast failed to disclose challenges in its business.
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.
The maker of Maltofer iron supplements is suing Arrotex over ads that claim its Ferro-grad C iron supplement is faster acting and reduces the risk of constipation.
A class action against Allergan over recalled breast implants is trying again to strike out the US drug company’s defence that there was no known causal link between its implants and a type of cancer at the time of supply.
A judge has suggested there may be merit in waiting for Johnson & Johnson to file a defence before deciding an application for a group costs order in a class action accusing the company of selling defective, carcinogenic talcum powder.
Former West Coast Eagles player Daniel Venables' case against two doctors and a neurologist has been struck out, with a judge finding he had failed to adequately plead a negligence case.
A class action against Allergan over recalled breast implants has lost its bid to strike out the US drug company’s defence that there was no known causal link between its implants and a certain form of cancer at the time of supply.
Norton Rose Fulbright has hired the former co-head of Baker McKenzie's Australian healthcare and life sciences group to join its corporate practice group in Sydney.